Tango therapeutics, inc.TNGX.US Overview
TNGX Overall Performance
TNGX AI Analysis & Strategy
TNGX Recent Performance
1.44%
Tango therapeutics, inc.
0.81%
Avg of Sector
-1.14%
S&P500
TNGX PowerScanner
TNGX Key Information
TNGX Valuation Metrics
TNGX Earnings Table
TNGX Profile
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.